Evidence map›Paper›PMID 42502321›Full record

ArticleBioactive materials2026

Exosomes delivering a high-throughput-screened RNA polymerase inhibitor for highly effective therapy of multidrug-resistant bacterial infected pneumonia.

Yiming Xiang, Ziya Gong, Juying Liu, Yizhou Zhu, Congyang Mao, Can Ai, Chaofeng Wang, Xiaofei Yang, Xiangmei Liu, Kelvin W K Yeung and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioactive materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yiming XiangHubei Key Laboratory of Medical Information Analysis and Tumor Diagnosis & Treatment, Key Laboratory of Cognitive Science, College of Biomedical Engineering, South-Central Minzu University, Wuhan, 430074, China.
Ziya GongHubei Key Laboratory of Medical Information Analysis and Tumor Diagnosis & Treatment, Key Laboratory of Cognitive Science, College of Biomedical Engineering, South-Central Minzu University, Wuhan, 430074, China.
Juying LiuHubei Key Laboratory of Medical Information Analysis and Tumor Diagnosis & Treatment, Key Laboratory of Cognitive Science, College of Biomedical Engineering, South-Central Minzu University, Wuhan, 430074, China.
Yizhou ZhuDepartment of Orthopaedics & Traumatology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, 999077, China.
Congyang MaoDepartment of Orthopaedics & Traumatology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, 999077, China.
Can AiDepartment of Orthopaedics & Traumatology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, 999077, China.
Chaofeng WangSchool of Life Science and Health Engineering, Hebei University of Technology, Tianjin, 300401, China.
Xiaofei YangHubei Key Laboratory of Medical Information Analysis and Tumor Diagnosis & Treatment, Key Laboratory of Cognitive Science, College of Biomedical Engineering, South-Central Minzu University, Wuhan, 430074, China.
Xiangmei LiuSchool of Life Science and Health Engineering, Hebei University of Technology, Tianjin, 300401, China.
Kelvin W K YeungDepartment of Orthopaedics & Traumatology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, 999077, China.
Shuilin WuSchool of Materials Science and Engineering, Peking University, Beijing, 100871, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bacterial pneumonia remains a primary global health threat, necessitating the development of novel therapeutic strategies to overcome escalating antibiotic resistance. In this study, we identified a highly active bacterial RNAP inhibitor, the repurposed semi-synthetic anthracycline hydrochloride Epirubicin (EPI), via the in silico high-throughput screening of a commercial library containing 16,563 small molecules. We identified EPI as a potent multi-target antibacterial agent. Alongside its intrinsic DNA intercalation properties, EPI heavily interferes with RNAP by targeting conserved catalytic residues (LYS838 and ASP1003), destabilizing the RNAP structure through a mechanism distinct from rifampicin.

Indexed as

AntibacterialBacterial pneumoniaExosome-based nanoplatformHigh-throughput screeningRNA polymerase inhibitor

Identifiers

PMID42502321
PMCPMC13400349

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.